消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2021 CSCO临床指南：胃癌的诊断和治疗（英文版）

中国临床肿瘤学会 中国临床肿瘤学会

治疗胃癌诊断

本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。

中文标题：

2021 CSCO临床指南：胃癌的诊断和治疗（英文版）

英文标题：

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

发布机构：

中国临床肿瘤学会

发布日期：

简要介绍：

本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a97061c00212583c, title=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）, enTitle=The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021, guiderFrom=中国临床肿瘤学会, authorId=0, author=, summary=本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。, cover=https://img.medsci.cn/202175/1625470678288_5433779.jpeg, journalId=0, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=null, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。</span></p>, tagList=[TagDto(tagId=65, tagName=治疗), TagDto(tagId=438, tagName=胃癌), TagDto(tagId=757, tagName=诊断)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=438, articleKeyword=胃癌, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=15920, appHits=942, showAppHits=0, pcHits=2485, showPcHits=14974, likes=4, shares=74, comments=40, approvalStatus=1, publishedTime=Mon Jul 05 15:40:21 CST 2021, publishedTimeString=null, pcVisible=1, appVisible=1, editorId=5433779, editor=Oranhyg是正经人, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=Oranhyg是正经人, createdTime=Mon Jul 05 15:38:09 CST 2021, updatedBy=5433779, updatedName=Oranhyg是正经人, updatedTime=Sat Jan 06 17:44:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf)])
2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf
下载请点击：
评论区 (26)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-03-15 吴卓远108

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-02-25 ms4000001880486183

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-11-04 ms2000000908561621

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-23 ms6000000590698351

    有中文吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 147c0641m47暂无昵称

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2017 嗜酸性筋膜炎的诊断标准，严重性分级和治疗指南

国外皮肤性病相关专家小组（统称） · 2017-12-13

2017 ASA立场声明：成人失眠症的心理/行为治疗

澳大拉西亚睡眠协会(ASA,Australasian Sleep Association) · 2017-06-20

2017 NAMS立场声明：激素治疗

北美绝经学会(NAMS,The North American Menopause Society) · 2017-06-24

解读2015年美国风湿病学会强直性脊柱炎和放射学阴性中轴型脊柱关节炎新的治疗推荐

暂未更新 · 2016-07-30

中国成人艰难梭菌感染诊断和治疗专家共识

暂未更新 · 2017-06-20

2016年中国超重/肥胖医学营养治疗专家共识解读

暂未更新 · 2017-05-30

拓展阅读

论文解读｜严俊/黄锐敏/庞涛联合团队揭示弥漫型胃癌中GXYLT2抑制PP2A而活化β-catenin

该研究通过构建新型分子分型系统，成功地筛选出与胃癌患者的肿瘤分期和不良生存结局呈正相关的糖苷木糖基转移酶2基因GXYLT2。

王湘教授谈胃癌治疗“新蓝海”：免疫治疗+生物标志物检测，开启精准时代

【医悦汇】有幸邀请到北京协和医院王湘教授做客对话大咖栏目，聚焦胃癌免疫治疗的最新进展与临床应用现状，深入探讨生物标志物在精准治疗中的关键作用，以及未来可能改变治疗格局的新方向。

JHO：中国胃癌和胃食管交界处癌诊断与治疗的现状

该研究生动反映了中国胃癌诊断和治疗实践的最新发展，为优化策略制定具有重要参考价值。

Gut | DNA甲基化新标志预测胃癌风险：一项多中心前瞻性研究揭示高危人群筛查新策略

本研究创新性地在临床高危人群中验证了DNA甲基化标志物RIMS1作为预测胃癌风险的有效工具。

Nature Medicine：阿里联手浙肿发布全球首个胃癌影像筛查AI模型，平扫CT+AI实现大规模胃癌早筛

浙江省肿瘤医院与阿里达摩院研发的胃癌影像筛查 AI 模型 DAMO GRAPE 登《Nature Medicine》，用平扫 CT 识别早期胃癌，提升检出率，具卫生经济学优势。

北肿沈琳团队研究登《柳叶刀》：胃癌进展或死亡风险降低63%！CAR-T治疗实体瘤新突破

该研究是“首个CAR-T疗法治疗实体瘤的随机对照试验”。基于本次研究结果，satri-cel有望成为CLDN18.2阳性晚期胃癌/食管胃结合部腺癌患者的三线治疗新选择。